This is the first approved drug for PAH that is thought to be disease modifying. MRK acquired sotatercept in the $11.5B buyout of XRLN in 2021 (#msg-166156870).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”